Sanofi and JHL Biotech have entered an agreement to expand their presence and develop modern therapies for patients in China.

According to the agreement, Sanofi will acquire all rights for the proposed biosimilar of Rituximab and other pipeline products from JHL Biotech, while the latter will be responsible for the development, registration and manufacturing of the products.

Sanofi will pay up to $326m in milestone payments and sales royalties to JHL Biotech and retain commercialisation rights to the products in China.

Breckenridge Pharmaceuticals and Gland Pharma have entered a multi-product marketing agreement.

According to the agreement, the former will be responsible to market and distribute seven injectable products in the US market.

The agreement enables Breckenridge to expand its injectable product portfolio.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

VBI Vaccines has completed the private placement of the debt financing, which has been subscribed to by Perceptive Advisors.

"Breckenridge Pharmaceuticals and Gland Pharma have entered a multi-product marketing agreement."

The company has raised $13m from the offering and intends to use the funds to increase the working capital and general corporate purposes.

Bluebird Bio has announced the underwritten public offering of 3.2 million of its common stock shares.

The company expects to raise gross proceeds of $294.9m through the offering, which is expected to be completed by 12 December.

Goodwin Procter is acting as the legal advisor for the offering.

The company plans to use the funds to further advance the development and clinical studies of the products for multiple myeloma, for commercial launch of LentiGlobin in Europe, and for other general corporate purposes.

Ixchelsis has raised $12m in a venture financing round led by Pfizer Venture Investments and TVM Life Sciences Ventures VII.

The company plans to invest the funds to advance the clinical study IX-01 in patients with severe premature ejaculation.